Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Short Interest Down 24.9% in January

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the recipient of a significant drop in short interest during the month of January. As of January 30th, there was short interest totaling 144,124 shares, a drop of 24.9% from the January 15th total of 192,015 shares. Based on an average trading volume of 181,961 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.0% of the company’s shares are short sold. Approximately 1.0% of the company’s shares are short sold. Based on an average trading volume of 181,961 shares, the days-to-cover ratio is currently 0.8 days.

Hedge Funds Weigh In On Kairos Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the business. FNY Investment Advisers LLC bought a new stake in shares of Kairos Pharma during the 3rd quarter worth $27,000. XTX Topco Ltd acquired a new position in Kairos Pharma during the second quarter worth about $44,000. Finally, Two Sigma Investments LP bought a new position in shares of Kairos Pharma in the third quarter worth about $54,000.

Kairos Pharma Stock Performance

Shares of NYSEAMERICAN KAPA traded up $0.00 during mid-day trading on Friday, reaching $0.60. The company had a trading volume of 98,183 shares, compared to its average volume of 131,442. The firm has a market cap of $12.45 million, a price-to-earnings ratio of -1.93 and a beta of 2.27. The business’s 50-day simple moving average is $0.75 and its 200 day simple moving average is $1.00. Kairos Pharma has a one year low of $0.40 and a one year high of $2.11.

Kairos Pharma (NYSEAMERICAN:KAPA) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

Separately, D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a research report on Wednesday, November 19th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $8.33.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.